4.6 Article

Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non-small cell lung cancer

期刊

RESPIROLOGY
卷 22, 期 7, 页码 1379-1385

出版社

WILEY
DOI: 10.1111/resp.13075

关键词

acute exacerbation; gender; age and physiology index; idiopathic pulmonary fibrosis; lung cancer; non-small cell lung cancer

资金

  1. AstraZeneca
  2. Boehringer Ingelheim
  3. Ono Pharmaceutical
  4. Eli Lilly
  5. Chugai Pharmaceutical
  6. Pfizer
  7. Takeda Pharmaceutical
  8. Taiho Pharmaceutical
  9. MSD

向作者/读者索取更多资源

Background and objective: Predicting the incidence rate of acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) and its prognosis in patients with non-small cell lung cancer (NSCLC) and IPF is difficult. The aim was to study the incidence of IPF-AE during the clinical course of the disease and its prognosis in patients with both NSCLC and IPF. Methods: In this retrospective study, we compared the incidence rate of AE during the clinical course of the disease as well as the 1-year survival rate and overall survival (OS) of patients with NSCLC and IPF using a modified gender, age and physiology (mGAP) staging system based on gender, age and percent predicted forced vital capacity. Results: Of 43 patients with NSCLC and IPF included in the final analysis, 17 patients (40%; 95% CI: 26-54%) experienced AE during the clinical course of the disease. One-year survival and median OS were 41.9% (95% CI: 28-57%) and 9.4 months, respectively. Further analysis showed that the incidence of IPF-AE gradually increased and that the 1-year survival rate and median OS gradually decreased with increasing mGAP index score and stage. Conclusion: Our study suggested that mGAP index score and cancer stage may predict IPF-AE and its prognosis in patients with NSCLC and IPF.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据